Drug Report History #278888

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.

Field Version v4-FR Version v3-EN
Language French (Updated) English
Date Updated 2026-03-10 2026-03-10
Drug Identification Number 02558238 02558238
Brand name YESAFILI YESAFILI
Common or Proper name Aflibercept Aflibercept
Company Name BIOSIMILAR COLLABORATIONS IRELAND LIMITED BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Ingredients AFLIBERCEPT AFLIBERCEPT
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVITREAL INTRAVITREAL
Packaging size Pre-filled Syringe Pre-filled Syringe
Anatomical Therapeutical Chemical (ATC) code S01LA S01LA
Anatomical Therapeutical Chemical (ATC) description OCULAR VASCULAR DISORDER AGENTS OCULAR VASCULAR DISORDER AGENTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date
Actual start date 2026-02-19 2026-02-19
Estimated end date 2026-03-16 2026-03-16
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments Delay due to disruption in drug product release. Yesafili vials 2 mg/0.05 mL (DIN 02535858) is available. Delay due to disruption in drug product release. Yesafili vials 2 mg/0.05 mL (DIN 02535858) is available.
Health Canada comments